- Home
- LYEL vs JRVR Comparison
LYEL vs JRVR Comparison
Compare LYEL & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- JRVR
- Stock Information
- Founded
- LYEL 2018
- JRVR 2002
- Country
- LYEL United States
- JRVR Bermuda
- Employees
- LYEL N/A
- JRVR N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- JRVR Property-Casualty Insurers
- Sector
- LYEL Health Care
- JRVR Finance
- Exchange
- LYEL Nasdaq
- JRVR Nasdaq
- Market Cap
- LYEL 203.9M
- JRVR 241.0M
- IPO Year
- LYEL 2021
- JRVR 2005
- Fundamental
- Price
- LYEL $0.57
- JRVR $4.83
- Analyst Decision
- LYEL Sell
- JRVR Buy
- Analyst Count
- LYEL 2
- JRVR 5
- Target Price
- LYEL $1.00
- JRVR $10.40
- AVG Volume (30 Days)
- LYEL 1.1M
- JRVR 349.8K
- Earning Date
- LYEL 02-26-2025
- JRVR 02-26-2025
- Dividend Yield
- LYEL N/A
- JRVR 3.32%
- EPS Growth
- LYEL N/A
- JRVR N/A
- EPS
- LYEL N/A
- JRVR N/A
- Revenue
- LYEL $63,000.00
- JRVR $796,817,000.00
- Revenue This Year
- LYEL N/A
- JRVR N/A
- Revenue Next Year
- LYEL N/A
- JRVR $7.46
- P/E Ratio
- LYEL N/A
- JRVR N/A
- Revenue Growth
- LYEL N/A
- JRVR 19.38
- 52 Week Low
- LYEL $0.55
- JRVR $4.35
- 52 Week High
- LYEL $3.26
- JRVR $11.49
- Technical
- Relative Strength Index (RSI)
- LYEL 34.11
- JRVR 52.98
- Support Level
- LYEL $0.56
- JRVR $4.54
- Resistance Level
- LYEL $0.62
- JRVR $4.84
- Average True Range (ATR)
- LYEL 0.04
- JRVR 0.12
- MACD
- LYEL 0.01
- JRVR 0.02
- Stochastic Oscillator
- LYEL 10.41
- JRVR 69.05
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure. and the Corporate and other segment consists of the management and treasury activities of holding companies, equity compensation for the group.